Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers
Neil E Fleshner, Nathan Lawrentschuk
Urology | ELSEVIER SCIENCE INC | Published : 2009
N. E, Fleshner serves as a consultant to AstraZeneca, Gk-coSmithKline, Merck, Sanofi-Aventis, Novartis, and Pfizer; he has received grant support for clinical trials from AstTaZeneca, GlaxoSmithKline, and Sanofi-Avenris. N. I.Awrentschuk has no conflicts to report.